Miguel Guerrero Moreno

Miguel Guerrero Moreno

Auto-generated profile, based on publicly available information

Miguel Guerrero Moreno

Department of Immunology and Microbiology, University of Colorado School of Medicine , Aurora, CO

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
RBRyan M. Baxter
Ryan M. Baxter
BCBerenice Cabrera-Martinez
Berenice Cabrera-Martinez
TGTusharkanti Ghosh
Tusharkanti Ghosh
CRCody Rester
Cody Rester
MMMiguel Guerrero Moreno
Miguel Guerrero Moreno
EHElena W. Y. Hsieh
Elena W. Y. Hsieh
The impact of B cell deficiency on the humoral and cellular responses to SARS-CoV2 mRNA vaccination remains a challenging and significant clinical management question. We evaluated vaccine-elicited serological and cellular responses in 1) healthy individuals who were pre-exposed to SARS-CoV-2 (n = 21), 2) healthy individuals who received a homologous booster (mRNA, n = 19; or Novavax, n = 19), and 3) persons with multiple sclerosis on B cell depletion therapy (MS-αCD20) receiving mRNA homologous boosting (n = 36). Pre-exposure increased humoral and CD4 T cellular responses in immunocompetent individuals. Novavax homologous boosting induced a significantly more robust serological response than mRNA boosting. MS-α CD20 had an intact IgA mucosal response and an enhanced CD8 T cell response to mRNA boosting compared with immunocompetent individuals. This enhanced cellular response was characterized by the expansion of only effector, not memory, T cells. The enhancement of CD8 T cells in the setting of B cell depletion suggests a regulatory mechanism between B and CD8 T cell vaccine responses.